MUC16

Across TCGA pan-cancer cohorts, MUC16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MUC16 data layer compared with 24 for mass-spec protein and 17 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MUC16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MUC16 expression acts as an unfavorable survival marker.

LUAD, HNSC, and PDAC are the cancer types where MUC16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.377	0.773	<.001	39	view →
HNSC	DFS	Tertile	All	0.333	1.000	.014	16	view →
PDAC	DFS	Median	III,IV	0.517	0.859	.006	13	view →
LSCC	DFS	Median	II,III,IV	0.869	0.969	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MUC16–LUAD (DFS)

Open the LUAD breakdown →